3Wk·

Then I thought...

0LIV3R · 2025-08-06T13:35:41.803671Z

... top, I was spared the $NOVO B I was spared the disaster, as I was hit in the face by $LNTH in the face 😵💫 ... please keep your fingers crossed that it gets $RKLB out tomorrow 🤞🏻 🚀 😜

... top, I was spared the $NOVO B (-0.32%) I was spared the disaster, as I was hit in the face by $LNTH (+0.74%) in the face 😵‍💫 ... please keep your fingers crossed that it gets $RKLB (+0.24%) out tomorrow 🤞🏻 🚀 😜

12 Comments

K@TechNav

3Wk

That's why I generally don't trust the health sector when it comes to investing...

•

0LIV3R@PIXELINVESTOR

3Wk

@TechNav the company is "healthy", the basic products are right and the pipeline is good... now I have to leave it invested for at least a year to get out of it... Does anyone else know another stock that will probably go through the roof soon where I can get it back in? 😂😂😂

••

K@TechNav

3Wk

@PIXELINVESTOR $UBER

••

0LIV3R@PIXELINVESTOR

3Wk

@TechNav Sure, the share price has been very volatile in recent months... Up down up and now down again... 😅 What do you expect from Uber?

••

K@TechNav

3Wk

@PIXELINVESTOR Up Down and YTD +44% (USD)
I expect 20 milliradian shares buyback... so 12.5% of their total brand cap. or ~1/10 of all shares will disappear like "magic"...

••

Gomerdoc@Gomerdoc

3Wk

@TechNav Well, erythropoietin was patented in 1984. It came onto the market in 1987, sold by Amgen to Roche because they could not produce it themselves (too small).

There are people who bought $AMGN back then ....😁👋🏽 and have kept it ever since:
And they would hardly share your view on the stability of the pharmaceutical sector ......😉🎉🍾🍾🍾🍾🎊

••

K@TechNav

3Wk

@Gomerdoc I think they were just lucky. The money that investors have burned in pharmaceutical companies is not seen to such an extreme in any other sector.
For every lucky health investor, there are thousands who have burned their fingers with promised cash flows, drugs and therapies.

P.S.: I am a biologist myself and work in the sector, having also worked in sales for major pharmaceutical companies.

••

Gomerdoc@Gomerdoc

3Wk

@TechNav then you are surely familiar with companies such as Amgen, Novo Nordisk and Roche (despite their recent problems): in the long term, and the long term means 25-30 years, their share price has only risen. Pfizer used to do the same.
Pharmaceuticals are must-have products that are in demand worldwide; nobody in the world can avoid them.
It doesn't always have to be the same company that runs forever: that's not the case in any industry. It's just that the healthcare sector is basically the same.
$SYK $COLO B $AMGN $JNJ:

Compare that with the IT/tech sector. IBM, Nokia, Intel, I'm still waiting for someone to show $NVDA how to build real chips (it won't take long, China sends its regards):
There is exactly the same problem as in the pharmaceutical industry. Or: not really a problem.

And Amgen in particular has nothing to do with luck. It simply has to do with solid dividends from the world's largest biotechnology company:

•

bull_investor_vkmhk@bull_investor_vkmhk

3Wk

I think we saw the bottom at $NOVO B. It was good or 😉😂.

•